Banco Santander S.A. Has $41.38 Million Holdings in Pfizer Inc. $PFE

Banco Santander S.A. lessened its stake in shares of Pfizer Inc. (NYSE:PFE) by 15.8% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 1,661,972 shares of the biopharmaceutical company’s stock after selling 311,163 shares during the quarter. Banco Santander S.A.’s holdings in Pfizer were worth $41,383,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Horizon Financial Services LLC raised its holdings in Pfizer by 174.8% during the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 645 shares during the period. Godfrey Financial Associates Inc. acquired a new position in Pfizer during the fourth quarter valued at $26,000. YANKCOM Partnership acquired a new position in Pfizer during the fourth quarter valued at $28,000. HFM Investment Advisors LLC raised its position in Pfizer by 61.0% during the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 427 shares during the period. Finally, Darwin Wealth Management LLC acquired a new position in Pfizer during the second quarter valued at $32,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. Royal Bank Of Canada raised Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price target on the stock in a research report on Tuesday. Zacks Research raised Pfizer from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. HSBC upped their price target on Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, March 17th. Guggenheim upped their price target on Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a research report on Tuesday, March 24th. Finally, CICC Research initiated coverage on Pfizer in a research report on Thursday, April 16th. They set an “outperform” rating and a $33.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Pfizer has a consensus rating of “Hold” and a consensus price target of $28.82.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s new weight-loss data is being viewed as encouraging for its obesity franchise, potentially improving the competitive case for its pipeline and helping sentiment around future growth. Article Title
• Positive Sentiment: Pfizer’s expanded U.S. label for HYMPAVZI is adding to optimism around the hemophilia business by widening the addressable patient pool, which may support future specialty-drug sales. Article Title
• Positive Sentiment: RBC recently upgraded Pfizer to Sector Perform, saying the valuation has reset and the risk-reward profile looks more balanced ahead of pipeline catalysts. Article Title
• Positive Sentiment: Some recent articles argue Pfizer’s Seagen oncology platform and newly acquired obesity assets could help offset patent-expiry and post-COVID revenue pressure, supporting a long-term turnaround thesis. Article Title
• Neutral Sentiment: Analysts currently rate Pfizer around Hold on average, suggesting the market sees limited near-term upside until more pipeline and commercial execution proves out. Article Title
• Negative Sentiment: Bearish commentary continues to highlight Pfizer’s dividend yield as a sign of underlying concern about cash flow, debt, and the company’s ability to support both payouts and reinvestment. Article Title

Pfizer Trading Up 0.1%

Shares of PFE stock opened at $26.19 on Friday. Pfizer Inc. has a 12 month low of $23.11 and a 12 month high of $28.75. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. The business’s 50 day moving average is $26.43 and its two-hundred day moving average is $26.32. The company has a market cap of $149.26 billion, a PE ratio of 19.99 and a beta of 0.34.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. The company had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm’s revenue was up 5.4% compared to the same quarter last year. During the same period last year, the business posted $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities analysts predict that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, June 12th. Shareholders of record on Friday, May 8th were issued a $0.43 dividend. The ex-dividend date of this dividend was Friday, May 8th. This represents a $1.72 dividend on an annualized basis and a yield of 6.6%. Pfizer’s dividend payout ratio (DPR) is 131.30%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.